Curanex Pharmaceuticals Inc Common Stock Net Assets
Curanex Pharmaceuticals Inc Common Stock net assets. Based on the latest financial reports, Curanex Pharmaceuticals Inc Common Stock (CURX) has net assets worth $14.29 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.48 Million) and total liabilities ($185.96K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Curanex Pharmaceuticals Inc Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.29 Million |
| % of Total Assets | 98.72% |
| Annual Growth Rate | 600.46% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 125.2 |
Net Assets of Curanex Pharmaceuticals Inc Common Stock (2022–2024)
Net assets of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024. This chart illustrates how Curanex Pharmaceuticals Inc Common Stock's net assets have evolved over time, based on quarterly financial data. See Curanex Pharmaceuticals Inc Common Stock (CURX) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Curanex Pharmaceuticals Inc Common Stock (2022–2024)
The table below shows the annual net assets of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024. For live market cap and overall valuation, see CURX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $503.36K | +737.68% |
| 2023-12-31 | $60.09K | +487.28% |
| 2022-12-31 | $10.23K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Curanex Pharmaceuticals Inc Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38070400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Curanex Pharmaceuticals Inc Common Stock Net Assets Breakdown (December 2024)
Curanex Pharmaceuticals Inc Common Stock net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.40K | 0.48% |
| Other Components | $1.12 Million | 223.18% |
| Total Equity | $503.36K | 100.00% |
Curanex Pharmaceuticals Inc Common Stock Competitors by Market Cap
The table below lists competitors of Curanex Pharmaceuticals Inc Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
A.G.Barr PLC
LSE:BAG
|
$7.99 Million |
|
Green Technology Metals Ltd
AU:GT1
|
$8.00 Million |
|
Focus Dynamics Group Bhd
KLSE:0116
|
$8.00 Million |
|
Nimy Resources Ltd
AU:NIM
|
$8.00 Million |
|
Mandrake Resources Ltd
AU:MAN
|
$7.99 Million |
|
Corus Entertainment Inc
TO:CJR-B
|
$7.98 Million |
|
Natural Health Trends Corp
F:NAH
|
$7.97 Million |
|
Quhuo Limited American Depository Shares
NASDAQ:QH
|
$7.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Curanex Pharmaceuticals Inc Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 60,090 to 503,360, a change of 443,270 (737.7%).
- Net loss of 361,506 reduced equity.
- New share issuances of 630,100 increased equity.
- Other factors increased equity by 174,676.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-361.51K | -71.82% |
| Share Issuances | $630.10K | +125.18% |
| Other Changes | $174.68K | +34.7% |
| Total Change | $- | 737.68% |
Book Value vs Market Value Analysis
This analysis compares Curanex Pharmaceuticals Inc Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 341.25x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25408.52x to 341.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $0.00 | $6.19 | x |
| 2023-12-31 | $0.00 | $6.19 | x |
| 2024-12-31 | $0.02 | $6.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Curanex Pharmaceuticals Inc Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -71.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-71.82%) is above the historical average (-100.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -197.74% | -77.82% | 2.54x | 1.00x | $-21.26K |
| 2023 | -31.95% | 0.00% | 0.00x | 1.24x | $-25.21K |
| 2024 | -71.82% | 0.00% | 0.00x | 1.03x | $-411.84K |
Industry Comparison
This section compares Curanex Pharmaceuticals Inc Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $14.29 Million | -197.74% | 0.01x | $7.99 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma… Read more